KR20190109926A - Composition for Anti-Arthritis Using a Leaf Extract of Ficus erecta Thunb. var. sieboldii(Miq.)King - Google Patents

Abstract

The present invention discloses the arthritis alleviating activity of a leaf extract of Ficus erecta confirmed through animal experiments. According to the present invention, it is possible to provide a composition for alleviating arthritis using the leaf extract of Ficus erecta. The composition for alleviating arthritis of the present invention can be commercialized as functional foods, drugs and the like.

Description

Composition for Anti-Arthritis Using a Leaf Extract of Ficus erecta Thunb. var. sieboldii (Miq.) King}

The present invention relates to a composition for improving arthritis using a ficus erecta Thunb.var.sieboldii (Miq.) King leaf extract.

According to the 1998 and 2001 National Health and Nutrition Examination, arthritis was a common chronic disease in over 45 years of age, and the prevalence of arthritis increased with age, accounting for 356.7 per thousand people in 1998 and 364.2 in 2001 for people over 65 years old. Korea National Health and Nutrition Examination Survey.2001.Ministry of Health and Welfare.Seoul, Korea.p 51). According to the recent statistics on elderly people in 2010, the proportion of elderly people aged 65 or older in Korea is 11%, and the prevalence of chronic degenerative diseases is increasing with the aging of the population, and the chronic disease with a high annual prevalence accounts for 43.1% or more. Senior Statistical Reports.2010.The Statistics Korea.Daejeon, Korea.p 5).

Arthritis is a disease that is accompanied by pain, stiffness, and swelling. The causes are degenerative changes, immune system abnormalities, infections, trauma, and metabolic disorders (J Knee Surg 24: 251-264, 2011). . Of these, osteoarthritis and rheumatoid arthritis (RA) arthritis account for 80% of all arthritis and account for the largest part of the burden of musculoskeletal disorders.

Osteoarthritis is a degenerative disease caused by the wear and tear of joint cartilage, which causes symptoms such as joint pain, muscle atrophy and muscle weakness. Many occur in the site (Obes. Rev. 7: 239-250, 2006; Arthritis Rheuma. 26: 1039-1049, 1986). Osteoarthritis is caused by various causes such as joint shock, inflammatory factors, abnormal hormone secretion, infection, degenerative changes, and genetic factors, but the exact cause has not been identified.

Factors related to the development of osteoarthritis are mainly known proteolytic enzymes, cytokines and the like. Metabolic processes in cartilage tissue play a pivotal role in the degeneration of cartilage tissue (Phytochemistry 7: 237-243, 2009), and typically matrix metalloproteinases (MMPs) are proteinases that destroy the matrix components of bone and cartilage. It is also expressed in pathological conditions such as arthritis and is known to play a major role in pathogenesis (Osteoarthritis Cartilage 9: 751-760, 2001; Clin Calcium 19: 1593-1601, 2009). MMPs with increased expression during arthritis include MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-7 and MMP-13 (Ann Rheum Dis 59: 455-461, 2000). ).

Narrow-leaved Thymeaceae is a plant belonging to the fig, also called a thin-leafed Thymeaceae, and it is a tree that grows mainly in Jeju Island and the southern coast of Korea, especially Jeju Island. It grows at the foot of the seashore and is 2 ~ 4m high. The bark is white with ash gray, dark brown cork, and hairless. The leaves are alternate, the lanceolate with the narrower bar, and the length is 10-20cm. The tip is pointed and the edge is flat or coarse. Side veins are 5 ~ 6 pairs, petiole is 1 ~ 4cm long (Lee Chang-bok, 1979, Korea Plant Book). In the private sector, the narrow leaf peonies have been used for a long time in 補 中 (보), 益氣 (益氣), 健脾 (脾), 비 (화), 强筋 壯骨 (ganglia), 消腫 (Sojong), 活 ( Live blood), detoxification.中 氣 虛弱 (medium weakness), 氣血 衰微 (blood pressure), Sadisan (less limb and dull limb), 筋骨 不利 (muscle bulge), bruises, 經 閉 (menopause), 産後 乳汁 缺乏 (postpartum milk deficiency) ) Has been used for treatment.

Antioxidative activity, anti-inflammatory activity, tyrosinase inhibitory activity, osteoporosis improving activity on narrow leaf perennial herb (Yoon Won Jong, Master's Thesis, Cheju National University, 2005; Sung Hwan Park, Master's Thesis, Cheju National University, 2011; Korean Patent Publication No. 2011-0056684 number)

The present invention discloses the arthritis improving activity of the narrow leaf zenith and leaf extract confirmed through animal experiments.

An object of the present invention to provide a composition for improving arthritis using a narrow leaf zenith and leaf extract.

Other and specific objects of the present invention will be presented below.

As confirmed in the following Examples and Experimental Examples, the present inventors have clearly improved the behavioral aspects (landing, limping, stepping, etc.) even in the osteoarthritis animal experiments by MIA (monosodium iodoacetate) Not only does it reduce the production of cytokines (IL-1β, TNF-α, IL-6) in a concentration-dependent manner, but it also significantly reduces the expression of MMP-2, 3, 7, 9, 13 and TIMP-1, 2. Confirmed. In addition, it was confirmed that the Formalin test, which is a test for the effects of continuous pain, in which tissue damage occurs, significantly suppressed chronic pain.

The present invention is provided based on the arthritis improvement effect confirmed through these animal experiments, the composition for arthritis improvement of the present invention is characterized in that it comprises a narrow leaf cheonseon and leaf extract as an active ingredient.

In the present specification, the "narrow leaf zenith and leaf extract" refers to the narrow leaf zenith and leaves to be extracted, such as water, methanol, ethanol, butanol lower alcohol having 1 to 4 carbon atoms, methylene chloride, ethylene, acetone, hexane, ether, chloroform , Extracts obtained by leaching using ethyl acetate, butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, carbon dioxide, An extract obtained by using a supercritical extracting solvent such as pentane or a fraction obtained by fractionating the extract, and the extraction method is cold, reflux, warm, ultrasonic radiation, supercritical in consideration of the polarity, the degree of extraction, and the degree of preservation of the active substance. Any method such as extraction may be applied. In the case of the fractionated extract, the fraction obtained by suspending the extract in a specific solvent and mixing and standing with a solvent having a different polarity, adsorbing the extract on a column filled with silica gel or the like, and then using a hydrophobic solvent, a hydrophilic solvent, or a mixed solvent thereof It is meant to include fractions obtained by mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or solid extract in which the extraction solvent is removed in a manner such as freeze drying, vacuum drying, hot air drying, spray drying, and the like. Preferably it refers to an extract obtained by using water, ethanol or a mixed solvent thereof as the extraction solvent, more preferably an extract obtained by using a mixed solvent of water and ethanol as the extraction solvent.

In addition, the term "active ingredient" as used herein means a component that can exhibit the desired activity alone or in combination with a carrier that is not active itself.

In addition, in the present specification, "arthritis" means osteoarthritis (degenerative arthritis), rheumatoid arthritis, purulent arthritis, ankylosing spondylitis, juvenile idiopathic arthritis or Still's disease.

In addition, in this specification, "arthritis improvement" is meant to include arthritis treatment, prevention, prevention of onset, delayed onset, alleviation of symptoms.

The active ingredient in the composition for improving arthritis of the present invention may be included in any amount (effective amount) depending on the purpose, formulation, formulation purpose, etc., as long as it can exhibit arthritis improving activity, and a typical effective amount is based on the total weight of the composition It will be determined in the range of 0.001% to 20.0% by weight. The term "effective amount" herein refers to a mammal, preferably a human subject, which may exhibit an intended medical and pharmacological effect, such as an arthritis-improving effect, when the composition of the present invention is administered to a mammal according to a recommendation of a medical professional or the like. , Refers to the amount of the active ingredient included in the composition of the present invention. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

Subjects to which the compositions of the invention can be applied (prescribed) are mammals and humans, in particular humans.

In addition to the active ingredient, the composition for improving arthritis of the present invention may further include any compound or natural extract known to have safety and arthritis improving activity for the enhancement and enhancement of the arthritis improving effect. Specifically, such compounds or extracts include glucosamine, N-acetylglucosamine, mucopolysaccharides, proteins, and dimethylsulfone (Dimethylsulfonylmethane) in the health functional food code (KFDA notification, standards and standards of health functional foods) according to the Act on Health Functional Foods. Complex extracts including CMO containing FAC (Fatty acid Complex), prickly edible extract, turmeric extract, glucosamine, chicken breast cartilage powder, rose hip powder, boswellia extract, beeswax Alcohols, complexes such as ginseng extract, fatty acid complexes, complex extracts such as perilla, green lipped mussel extract oil, hop extracts, complexes such as golden extracts, and the like. Such compounds or natural extracts may be included in the composition for improving arthritis of the present invention with one or more active ingredients thereof.

The composition for arthritis improvement of this invention can be grasped | ascertained as a food composition in another specific aspect.

The food composition of the present invention may be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, ionic beverages, processed oils such as milk, yogurt, gums, rice cakes, sweets, bread, sweets, noodles, and the like. It can be prepared as a dietary supplement, such as foods, tablets, capsules, pills, granules, liquid, powder, flaky, paste, syrup, gel, jelly, bar. In addition, the food composition of the present invention can distinguish any product as long as it conforms to the enforcement regulations at the time of manufacture and distribution in the legal and functional divisions. For example, it may be a health functional food according to the Act on Health Functional Foods, or soy milk, fermented beverages, special purpose foods, etc. according to each food type in the Food Code of the Food Sanitation Act (KFDA notice, standards and standards of food).

The food composition of the present invention may include food additives in addition to the active ingredient. Food additives are generally understood as substances that are added to, mixed with, or infiltrated in the manufacture, processing, or preservation of foods, and because they are taken daily with food for a long time, their safety should be ensured. The Food Additives Code of the Food Sanitation Act (KFDA Notification, Food Additives Standards and Standards) defines the food additives that are guaranteed to be safe by dividing them into chemical synthetics, natural additives, and mixed preparations.

These food additives may be divided into sweeteners, flavors, preservatives, emulsifiers, acidulants, thickeners, and the like in terms of their functionalities.

Sweeteners may be used in amounts that give the food a suitable sweet taste, and may be natural or synthetic. Preferably, a natural sweetener is used. Examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavoring agents can be used to enhance the taste or aroma, both natural and synthetic. It is the case of using a natural thing preferably. In addition to flavors, the use of natural ones can be combined with nutritional purposes. The natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like. In addition, ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo and the like can also be used. Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavoring agents may be used, and synthetic flavoring agents may include esters, alcohols, aldehydes, terpenes, and the like.

Sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid) and the like can be used as a preservative, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, Pectin etc. can be mentioned, As acidic acid, acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, etc. can be used. The acidulant may be added so that the food composition is at an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing the taste.

As the thickener, suspending implementers, sedimenting agents, gel formers, swelling agents and the like can be used.

In addition to the food additives described above, the food composition of the present invention may include a bioactive substance or minerals known in the art for the purpose of supplementing and reinforcing the functionality and nutritional properties and ensuring the stability as a food additive.

Examples of such physiologically active substances include catechins, vitamin B1, vitamin C, vitamin E, vitamin B12 and the like, tocopherol, dibenzoylthiamine and the like contained in green tea, and the like, and calcium minerals such as calcium citrate, magnesium stearate Magnesium preparations such as iron, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc and the like.

In the food composition of the present invention, the food additive as described above may be included in an amount that can achieve the purpose of addition according to the product type.

Regarding other food additives that may be included in the food composition of the present invention, reference may be made to food or food additives.

The composition for improving arthritis of the present invention can be understood as a pharmaceutical composition in a specific embodiment.

The pharmaceutical compositions of the present invention may be prepared in oral or parenteral formulations according to the route of administration by conventional methods known in the art, including pharmaceutically acceptable carriers in addition to the active ingredient. "Pharmaceutically acceptable" here means that the subject of application (prescription) is not toxic as far as adaptable without inhibiting the activity of the active ingredient.

When the pharmaceutical composition of the present invention is prepared in an oral dosage form, powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, suspensions, wafers according to methods known in the art with suitable carriers It may be prepared in a formulation such as. Examples of suitable pharmaceutically acceptable carriers include lactose, glucose, sucrose, dextrose, sugars such as sorbitol, mannitol, xylitol, starch such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, Celluloses such as sodium carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable Yu etc. can be mentioned. If formulated, it may be formulated to include diluents and / or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, if necessary.

When the pharmaceutical compositions of the present invention are prepared in parenteral formulations, they may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories with suitable carriers according to methods known in the art. When formulated as an injection, suitable carriers include sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof. Preferably, PBS (phosphate buffered saline) containing Ringer's solution or triethanol amine or sterile water for injection , Isotonic solutions such as 5% dextrose, and the like can be used. When formulated as a transdermal administration, it may be formulated in the form of an ointment, cream, lotion, gel, external solution, pasta, linen, aerosol and the like. Nasal inhalants can be formulated in the form of aerosol sprays using suitable propellants such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. The bases of suppositories are witepsol, twin (tween) 61, polyethylene glycols, cacao butter, laurin paper, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters and the like can be used.

Regarding the formulation of pharmaceutical compositions, it is known in the art and specific reference may be made to Remington's Pharmaceutical Sciences (19th ed., 1995) and the like. The document is considered part of this specification.

Preferred dosages of the pharmaceutical compositions of the present invention range from 0.001 mg / kg to 10 g / kg per day, preferably 0.001 mg / kg to 1 g, depending on the condition, body weight, sex, age, severity of the patient and route of administration. It can range from / kg. Administration can be done once a day or divided into several times. Such dosage should not be construed as limiting the scope of the invention in any aspect.

In another aspect, the present invention provides a composition for improving chronic pain, including narrow leaf zenith and leaf extract as an active ingredient. With respect to the active ingredient of the composition for improving chronic pain of the present invention, the aspect of application to the food or drug composition, etc., the above-described bar may be applied mutatis mutandis to the composition for improving arthritis of the present invention.

As described above, according to the present invention can provide a composition for improving arthritis using a narrow leaf zenith and leaf extract. The composition for improving arthritis of the present invention can be commercialized as a functional food, drugs and the like.

1 and 2 are the results showing the changes in weight and parking behavior by parking in MIA induced osteoarthritis animal model, respectively.
3 to 5 are the results of measuring the inflammatory cytokines (IL-1β, TNF-α, IL-6) in MIA induced osteoarthritis animal model.
6 to 12 are the results of confirming the mRNA expression levels of MMP-2, 3, 4, 9, 13 and TIMP-1, 2 in MIA-induced osteoarthritis nonclinical animal model by real-time PCR.
13 shows the results of H & E staining of experimental animal cartilage tissue in a osteoarthritis model by MIA.
14 is a chronic pain animal experiment results.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

< Example > Preparation of Narrow Leaf Lines and Leaf Extracts

Narrow leaf zenith and leaves were dried and pulverized, immersed in 20% of 70% ethanol, stirred for 18 hours at room temperature, extracted and filtered. The filtrate was concentrated under reduced pressure and lyophilized to obtain a powdery extract. The extract thus obtained was used in the animal experiment below while refrigerated.

< Experimental Example > MIA (monosodium iodoacetate Osteoarthritis Animal Experiment and Chronic Pain Animal Experiment

Experimental Example 1 Osteoarthritis Animal Experiment by MIA (monosodium iodoacetate)

1. Experiment Method

(1) Induction of Osteoarthritis by MIA

Drug-induced model is a method to induce osteoarthritis by injecting a specific drug into the experimental animal by intra-articular injection, etc. to inhibit the metabolism of chondrocytes or damage ligament and tendon.In this experiment, MIA (monosodium iodoacetate) Was used to cause osteoarthritis.

After cleansing the area around the knee, 50 μl (60 mg / mL) of osteoarthritis-inducing substance MIA (Monosodium iodoacetate) was administered to the right knee joint cavity using a 1 mL syringe. When diluting MIA, 0.9% saline was used. After 7 days of MIA administration, the presence of osteoarthritis was confirmed, and only animals with osteoarthritis were used in the experiment.

(2) Test substance administration, weight measurement, and behavior change by parking

Body weights were measured once a week and behavioral scores were measured by parking. Narrow leaf zenith and leaf extract (FES, dose 250, 500 mg / kg) of the test substance as an example were administered daily in the morning during the experimental period, the measurement was made in the afternoon. The measurement was performed on 7, 7, and 21 days after oral administration of the test substance into the feed. The positive control group used indomethacin, a type of nonsteroidal drug (NSAID).

(3) biological indicator testing

Blood and synovial fluid were collected before and after dosing or at regular intervals throughout the dosing period. After separating serum or plasma from blood, cytokines such as IL-1β, TNF-α, IL-6 as inflammatory markers were measured by ELISA. In addition, the expression of MMP-2, 3, 7, 9, 13 and TIMP-1, 2 was measured using synovial fluid to confirm the degree of cartilage destruction. After the administration is completed, the synovial tissue is collected from the corpse of the experimental animal, RNA is isolated, and MMP-2, 3, 7, 9, 13 and TIMP-1 by PCR or the like using the primers shown in Table 1 below. , MRNA expression levels of 2 and the like were analyzed. Specifically, total RNA extracted from rat tissue was used TRI-reagent (MRC, Cincinnati, OH, USA), and was made under RNase-free conditions. 1 μg total RNA was added with oligo (dT) 18 primer, dNTP (0.5 μM), 1 unit RNase inhibitor and M-MuLV reverse transcriptase (2U) at 70 ° C 5 min, 25 ° C 5 min, 37 ° C 60 min, and 70 CDNA was synthesized by heating at 10 ° C. for 10 min. For quantitative real-time polymerase chain reaction (qRT-PCR), 2 μl cDNA, 12.5 μl master mix [SYBR premix Ex Taq II (Takara, Japan)], 1 μl each primer (Table 1), 8.5 After mixing the μL DW, the expression pattern of each gene was measured in real time using MX3005P (Stratagene, USA). At this time, the PCR cycle was repeated 10 minutes at 95 ℃, 95 ℃ / 15 seconds and 60 ℃ / 60 seconds for 40 cycles, the cycle threshold (CT) of each measured gene was compared with the control group to calculate the expression amount .

(4) H & E staining of experimental animal cartilage tissue

After the experiment, the rats were sacrificed and the knee joints were collected for histopathological observation. Immediately after extraction for fixation of the knee joint, it was fixed for 24 hours with 10% formaldehyde (Junsei, Tokyo, Japan) and demineralized by exchanging solution for 72 hours at 24-hour intervals with Calci-Clear Rapid (National Diagnostics, Atlanta, GA, USA). Was carried out. The fabrication and cooling of paraffin blocks were performed using an automatic embedding device (Tissue-Tex 4701, Sakura Co., Tokyo, Japan). The fabricated block was sequentially sliced into 7 m thick tissue in a vertical direction using a rotary michrotome 2040 (Sakura Co.), and attached to the slide through a floating hot water bath and an extension process. The prepared tissue slides were subjected to Hematoxylin & Eosin (H & E) staining to evaluate the degree of inflammatory infiltration.

2. Experimental Results

(1) weight change in osteoarthritis model by MIA and By parking  Action result

Parking weight change in the MIA-induced osteoarthritis model is shown in FIG. 1, and parking change in the MIA-induced osteoarthritis model is shown in FIG.

In the model of osteoarthritis induced by MIA, weekly weight change was observed in all groups, but there was no difference in body weight.

As a result of measuring the change of behavior by parking according to the criteria of [Table 2] below, the behavioral score by parking began to decrease from week 1 compared with MIA-treated arthritis-induced model treatment group (MIAC) in the test substance-administered group. The decrease was lower than that of the positive control indomethacin (IM) (p <0.05).

(2) Biochemical Indicator Changes in the Osteoarthritis Model by MIA

Blood and synovial fluids were collected before and after administration to confirm biochemical marker changes in the MIA-induced osteoarthritis model. After separating serum or plasma from blood, cytokines such as IL-1β, TNF-α, IL-6 as inflammatory markers were measured using an ELISA assay kit, and the results are shown in FIGS. 3 to 5. As a result of the administration of the narrow leaf zenith and leaf extract, it was confirmed that the inhibition of the production of inflammatory markers in a concentration-dependent manner compared to the MIA-treated osteoarthritis-induced model (MIAC).

(3) Biochemical Indicators in Cartilage Tissue in Osteoarthritis Model by MIA

MMP-2, 3, 7, 9, 13, and biochemical indicators that break down cartilage and destroy the matrix components of bone and cartilage after completion of administration to confirm biochemical marker changes in MIA-induced osteoarthritis models. MRNA expression level for TIMP-1, 2 was confirmed by real-time PCR, and the results are shown in [FIGS. 6 to 12]. As a result of the administration of the narrow leaf zenith and leaf extract, it was confirmed that the mRNA expression was significantly inhibited in all biochemical markers compared to the MIA-treated osteoarthritis-induced model (MIAC).

(4) H & E staining of experimental animal cartilage tissue in MIA osteoarthritis model

In order to confirm the effect of the narrow leaf pericardium and leaf extract on the knee joint and cartilage tissue, the results of H & E staining were performed [FIG. 13], and osteoarthritis was induced in the MIA-only osteoarthritis induction model (MIAC). The synovial and fibrous tissues were remarkably deformed, whereas the narrow leaf periphery and extract-treated group recovered similarly to the normal group.

Experimental Example 2 chronic pain animal experiment-Formalin test

1. Experimental Method-Formalin test

Formalin test is a test for the effects of persistent pain in tissue damage against harmful stimuli. The number of flinching behaviors of the paws administered in 3 minutes after subcutaneous injection of 10% formalin into the hind paws of rats was measured. Flinching behavior is divided into Phase 1 (0-12 minutes) and Phase 2 (24-39 minutes) .At the first phase, 5-10 minutes after formalin administration as acute pain behavior due to afferent C-fiber excitation caused by invasive stimulation. It continues and disappears. Phase 2 measures peripheral nervous system-related pain caused by inflammation-related substances, such as prostagladins, and complex pain due to central nervous sensitization. The pain response is seen over 20-60 minutes. The initial pain response following formalin injection is due to direct stimulation to the nociceptors and the later pain response is due to central sensitization. Narrow leaf zenith and extract were orally administered at 60 mg / kg and 500 mg / kg 60 minutes before the start of the experiment, respectively.

2. Experimental Results

The results are shown in [FIG. 14]. Referring to FIG. 14, it was confirmed that Phase 1 was significantly inhibited in comparison with the control group at 500 mg / kg, and in Phase 2, both the narrow leaf periphery and the extract administration group were significantly inhibited compared to the control group (p <0.05).

Claims (8)

Arthritis improving composition comprising a narrow leaf zenith and leaf extract as an active ingredient.
The method of claim 1,
The extract is a composition for improving arthritis, characterized in that obtained by extracting the narrow leaf zenith and leaves with water, ethanol, or a mixed solvent thereof.
The method of claim 1,
The arthritis is a composition for improving arthritis, characterized in that the osteoarthritis or rheumatoid arthritis.
The method according to any one of claims 1 to 3,
The composition is an arthritis improving composition, characterized in that the food composition.
The method according to any one of claims 1 to 3,
The composition is a composition for improving arthritis, characterized in that the pharmaceutical composition.
Analgesic composition comprising a narrow leaf zenith and leaf extract as an active ingredient.
The method of claim 6,
The composition for analgesic, characterized in that the food composition.
The method of claim 6,
The composition for analgesic, characterized in that the pharmaceutical composition.

Images